Clinical Trial Update: High Dose Somatostatin Analogues in Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating high-dose somatostatin analogues in neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Gastrointestinal Neuroendocrine Tumor
• Lung Cancer
• Multiple Endocrine Neoplasia
• Neuroendocrine Tumor
• Pancreatic Cancer
• Pancreatic Neuroendocrine Tumor
• Thymic Cancer

Drugs mentioned

• High-dose somatostatin analogue

Snippet

Sponsor: Federico II University | Conditions: Respiratory Tract Neoplasms, Thymic Neoplasms | Phase 2 | Status: COMPLETED